Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway

Cancer Research

Volumn 71, Issue 24, 2011, Pages 7547-7557

  Liu, Haiou ^a,b   Xu, Jiejie ^a   Zhou, Lei ^a   Yun, Xiaojing ^a   Chen, Lin ^a   Wang, Shanshan ^a   Sun, Linlin ^a   Wen, Yumei ^a   Gu, Jianxin ^a  

^a FUDAN UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAF1 PROTEIN; SARACATINIB; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

AGED; AGED, 80 AND OVER; ANIMALS; BENZODIOXOLES; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; FEMALE; HEPATITIS B SURFACE ANTIGENS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE C-ALPHA; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; PROTO-ONCOGENE PROTEINS PP60(C-SRC); QUINAZOLINES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VERO CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84255200363     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2260     Document Type: Article

References (42)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-94. (Pubitemid 38032767)
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45. (Pubitemid 27527771)
3. Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology 2009;49(5 Suppl):S56-60.
4. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-87. (Pubitemid 44286000)
5. Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 2010;52:594-604.
6. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004;127(5 Suppl 1):S56-61. (Pubitemid 39423370)
7. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;350:1118-29. (Pubitemid 38298992)
8. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68. (Pubitemid 30143840)
9. Babinet C, Farza H, Morello D, Hadchouel M, Pourcel C. Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. Science 1985;230:1160-3. (Pubitemid 16170002)
10. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989;59:1145-56. (Pubitemid 20024625)
11. Toshkov I, Chisari FV, Bannasch P. Hepatic preneoplasia in hepatitis B virus transgenic mice. Hepatology 1994;20:1162-72. (Pubitemid 24323561)
12. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008;48:2047-63.
13. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.
14. Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010;52:921-9.
15. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010;29:4989-5005.
16. Ito Y, Kawakatsu H, Takeda T, Sakon M, Nagano H, Sakai T, et al. Activation of c-Src gene product in hepatocellular carcinoma is highly correlated with the indices of early stage phenotype. J Hepatol 2001;35:68-73. (Pubitemid 32646226)
17. Masaki T, Okada M, Shiratori Y, Rengifo W, Matsumoto K, Maeda S, et al. pp60c-src activation in hepatocellular carcinoma of humans and LEC rats. Hepatology 1998;27:1257-64. (Pubitemid 28227852)
18. Klein NP, Schneider RJ. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. Mol Cell Biol 1997;17:6427-36. (Pubitemid 27451188)
19. Tian X, Zhao C, Zhu H, She W, Zhang J, Liu J, et al. Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection. J Virol 2010;84:3373-81.
20. Wang YX, Xu X, Luo C, Ma ZM, Jiang HL, Ding JP, et al. A putative new domain target for anti-hepatitis B virus: residues flanking hepatitis B virus reverse transcriptase residue 306 (rtP306). J Med Virol 2007;79:676-82. (Pubitemid 46709361)
21. Zhu X, Chen S, Yin X, Shen A, Ji S, Shen Z, et al. Constitutively active PKB/Akt inhibited apoptosis and down-regulated beta1,4-galactosyl-transferase 1 in hepatocarcinoma cells. Biochem Biophys Res Commun 2003;309:279-85. (Pubitemid 37025888)
22. Liu W, Shen X, Yang Y, Yin X, Xie J, Yan J, et al. Trihydrophobin 1 is a new negative regulator of A-Raf kinase. J Biol Chem 2004;279:10167-75. (Pubitemid 38372621)
23. Xu J, Yun X, Jiang J, Wei Y, Wu Y, Zhang W, et al. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology 2010;52:142-54.
24. Zhang W, Xu W, Xiong S. Blockade of Notch1 signaling alleviates murine lupus via blunting macrophage activation and M2b polarization. J Immunol 2010;184:6465-78.
25. Zhang W, Xu W, Xiong S. Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component. J Immunol 2011;187:1764-77.
26. Remmele W, Stegner HE. Recommendation for uniformdefinition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-40.
27. Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH. The PreS2 activator MHBs(t) of hepatitis Bvirus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J 2002;21:525-35. (Pubitemid 34174034)
28. Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol 2003;39 Suppl 1:S59-63. (Pubitemid 37222648)
29. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 2006;25:3823-33. (Pubitemid 43980478)
30. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S303-9. (Pubitemid 39423400)
31. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003;22:5093-107. (Pubitemid 37059591)
32. Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000;10:211-31. (Pubitemid 30614221)
33. Hildt E, Saher G, Bruss V, Hofschneider PH. The hepatitis B virus large surface protein (LHBs) is a transcriptional activator. Virology 1996;225:235-9. (Pubitemid 26390072)
34. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
35. Branda M, Wands JR. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 2006;43:891-902. (Pubitemid 43724611)
36. Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 2007;46:590-7. (Pubitemid 47344795)
37. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6. (Pubitemid 44050137)
38. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-59. (Pubitemid 41400849)
39. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52. (Pubitemid 46144363)
40. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69:7385-92.
41. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998;27:951-8. (Pubitemid 28160479)
42. Liu HY, Wen GB, Han J, Hong T, Zhuo D, Liu Z, et al. Inhibition of gluconeogenesis in primary hepatocytes by stromal cell-derived factor-1 (SDF-1) through a c-Src/Akt-dependent signaling pathway. J Biol Chem 2008;283:30642-9.